TIDMMDC
RNS Number : 9151C
Mediclinic International plc
20 June 2019
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
South African income tax number: 9950122714
("Mediclinic", the "Company" or the "Group")
20 June 2019
TAX TREATMENT OF ORDINARY SHARE DIVIDEND FOR SHAREHOLDERS ON THE
SOUTH AFRICAN REGISTER
Background
Shareholders on the South African register of the Company are
referred to Mediclinic's announcement of the results for the year
ended 31 March 2019 and proposed dividend announcement released on
the Stock Exchange News Service and on the Regulatory News Service
on 23 May 2019, confirming that the Board of Directors of
Mediclinic had proposed a final dividend from retained earnings of
4.70 pence per ordinary share for the year ended 31 March 2019 for
approval by the Company's shareholders at the annual general
meeting on Wednesday, 24 July 2019.
The final dividend will be paid on Monday, 29 July 2019 to all
ordinary shareholders who are on the register of members at the
close of business on the record date of Friday, 14 June 2019.
Shareholders on the South African register will be paid the ZAR
cash equivalent of 86.24500 cents (68.99600 cents net of dividend
withholding tax) per share. A dividend withholding tax of 20% will
be applicable to all shareholders on the South African register who
are not exempt therefrom. The ZAR cash equivalent has been
calculated using the following exchange rate: GBP1: ZAR18.35, being
the 5-day average GBP/ZAR exchange rate (Bloomberg) on Friday, 17
May 2019 at 3:00pm GMT.
Tax treatment for shareholders on the South African register
South African tax resident shareholders on the South African
register:
In terms of the Company's Dividend Access Trust structure,
eligible South African tax resident shareholders on the South
African register set out below will receive a component of the
dividend, namely 85.21178 cents per share, from the Dividend Access
Trust and therefore regarded as a local South African dividend,
with the remaining component, namely 1.03322 cents per share, being
received from the Company and therefore regarded as a foreign
non-South African dividend. For purposes of South African dividend
withholding tax, the entire dividend of 86.24500 cents per share is
taxable at a rate of 20%, unless an applicable exemption
applies:
1. in the case of shares held in certificated form, eligible
shareholders who are registered on the South African
register with an address in South Africa (other than
PLC Nominees Proprietary Limited (or any successor
entity through which shares held in dematerialised
form are held); and
2. in the case of shares held in dematerialised form,
in respect of whom the South African transfer secretaries
of the Company have determined, in good faith and by
reference to the information provided to them by the
eligible shareholders and/or their brokers and/or central
securities depository participants, that such eligible
shareholders are either (i) tax resident in South Africa
or (ii) have an address in South Africa and have not
expressly indicated that they are not tax resident
in South Africa as at the dividend record date.
Non-South African tax resident shareholders on the South African
register:
Non-South African tax resident shareholders on the South African
register will be paid the dividend by the Company in the usual way
and not through the Dividend Access Trust. The entire dividend of
86.24500 cents per share payable to such shareholders will
therefore be regarded as a foreign dividend and exempt from South
African dividend withholding tax, provided that the relevant
exemption forms have been completed and submitted as
prescribed.
About Mediclinic International plc
Mediclinic is an international private healthcare services
group, established in South Africa in 1983, with divisions in
Switzerland, Southern Africa (South Africa and Namibia) and the
United Arab Emirates.
The Group's core purpose is to enhance the quality of life.
Mediclinic is focused on providing specialist-orientated,
multi-disciplinary services across the
continuum of care in such a way that the Group will be regarded
as the most respected and trusted provider of healthcare services
by patients, medical practitioners, funders and regulators of
healthcare in each of its markets.
Mediclinic comprises 77 hospitals, five sub-acute hospitals, 12
day case clinics and 21 outpatient clinics. Hirslanden operates 18
hospitals, two day case clinics and three outpatient clinics in
Switzerland with more than 1 900 inpatient beds; Mediclinic
Southern Africa operates 52 hospitals, five sub-acute hospitals and
12 day case clinics with more than 8 500 inpatient beds; and
Mediclinic Middle East operates seven hospitals, two day case
clinics and 21 outpatient clinics with more than 900 inpatient beds
in the United Arab Emirates.
The Company's primary listing is on the London Stock Exchange
('LSE') in the United Kingdom, with secondary listings on the JSE
Ltd in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group
plc, a leading private healthcare group based in the United Kingdom
and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569
Investor queries
James Arnold, Head of Investor Relations, Mediclinic
International plc
+44 (0)20 3786 8181
ir@mediclinic.com
Media queries
FTI Consulting
Deborah Scott/Brett Pollard - United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V
7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International
plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank
Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DIVURSRRKAANUAR
(END) Dow Jones Newswires
June 20, 2019 09:00 ET (13:00 GMT)
Mediclinic (LSE:MDC)
Historical Stock Chart
From Apr 2024 to May 2024
Mediclinic (LSE:MDC)
Historical Stock Chart
From May 2023 to May 2024